Cumberland Pharmaceuticals (NASDAQ:CPIX) had its price objective lowered by B. Riley from $9.25 to $8.75 in a research note released on Friday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Separately, ValuEngine raised shares of Cumberland Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, May 2nd.

Shares of CPIX opened at $5.50 on Friday. The company has a current ratio of 4.10, a quick ratio of 3.70 and a debt-to-equity ratio of 0.20. The company has a market cap of $92.69 million, a P/E ratio of -78.57 and a beta of 0.65. Cumberland Pharmaceuticals has a 1 year low of $5.50 and a 1 year high of $7.96.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, August 14th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The business had revenue of $10.16 million for the quarter, compared to the consensus estimate of $9.94 million. Cumberland Pharmaceuticals had a negative net margin of 22.65% and a negative return on equity of 4.37%. equities analysts predict that Cumberland Pharmaceuticals will post -0.24 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in CPIX. Ariel Investments LLC lifted its stake in shares of Cumberland Pharmaceuticals by 28.7% during the second quarter. Ariel Investments LLC now owns 1,305,052 shares of the specialty pharmaceutical company’s stock valued at $8,000,000 after buying an additional 291,126 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Cumberland Pharmaceuticals by 6.7% during the second quarter. Renaissance Technologies LLC now owns 377,209 shares of the specialty pharmaceutical company’s stock valued at $2,312,000 after buying an additional 23,709 shares during the period. Finally, Prudential Financial Inc. purchased a new position in shares of Cumberland Pharmaceuticals during the first quarter valued at approximately $138,000. 34.52% of the stock is currently owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. Its marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects.

Further Reading: Fundamental Analysis and Choosing Stocks

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.